Answers are grounded in this paper and cite their sources.
A study demonstrates that amifampridine does not improve outcomes in myasthenia gravis patients compared to pyridostigmine alone, suggesting caution in its use.
This study provides Class I evidence that in patients with AChRAb+ MG, the addition of amifampridine to pyridostigmine was not superior to treatment with pyridostigmine alone and was associated with a higher incidence of adverse events.
No takes yet. Share an insight, caveat, or question.
Remijn-Nelissen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: